Combined Sub-Optimal Doses of Rosuvastatin and Bexarotene Impair Angiotensin II-Induced Arterial Mononuclear Cell Adhesion Through Inhibition of Nox5 Signaling Pathways and Increased RXR/PPARα and RXR/PPARγ Interactions

Antioxidants and Redox Signaling

Volumn 22, Issue 11, 2015, Pages 901-920

  Escudero, Paula ^a,b   De Marañón, Aranzazu Martinez ^a   Collado, Aida ^a   Gonzalez Navarro, Herminia ^b   Hermenegildo, Carlos ^b,c   Peiró, Concepción ^a   Piqueras, Laura ^b   Sanz, Maria Jesus ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; APOCYNIN; APOLIPOPROTEIN E; BEXAROTENE; CXCL1 CHEMOKINE; FRACTALKINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RANTES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 5; RETINOID X RECEPTOR ALPHA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ROSUVASTATIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ANTINEOPLASTIC AGENT; FLUOROBENZENE; MEMBRANE PROTEIN; NOX5 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PYRIMIDINE DERIVATIVE; RETINOID X RECEPTOR; SULFONAMIDE; TETRALIN DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL MONONUCLEAR CELL; ARTERY ENDOTHELIUM; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; BIOAVAILABILITY; C57BL 6 MOUSE; CELL ADHESION; CELL INTERACTION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; LEUKOCYTE ADHERENCE; MICROCIRCULATION; MONONUCLEAR CELL; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; ARTERY; CELL LINE; DRUG EFFECTS; METABOLISM;

MUS;

ANGIOTENSIN II; ANTICARCINOGENIC AGENTS; ARTERIES; CELL ADHESION; CELL LINE; FLUOROBENZENES; HUMANS; LEUKOCYTES, MONONUCLEAR; MEMBRANE PROTEINS; NADPH OXIDASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PYRIMIDINES; RETINOID X RECEPTORS; ROSUVASTATIN CALCIUM; SIGNAL TRANSDUCTION; SULFONAMIDES; TETRAHYDRONAPHTHALENES;

EID: 84926330020     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.5969     Document Type: Article

References (62)

1. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 62: 10J-15J, 1988.
2. Alvarez A, Cerda-Nicolas M, Naim Abu Nabah Y, Mata M, Issekutz AC, Panes J, Lobb RR, and Sanz MJ. Direct evidence of leukocyte adhesion in arterioles by angiotensin II. Blood 104: 402-408, 2004.
3. Balakumar P and Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol 165: 373-379, 2012.
4. Cernuda-Morollon E and Ridley AJ. Rho GTPases and leukocyte adhesion receptor expression and function in endothelial cells. Circ Res 98: 757-767, 2006.
5. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, and Landreth G. Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280: 34202-34209, 2005.
6. Desjardins F, Sekkali B, Verreth W, Pelat M, De Keyzer D, Mertens A, Smith G, Herregods MC, Holvoet P, and Balligand JL. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J 29: 128-137, 2008.
7. de Vries-van der Weij J, de Haan W, Hu L, Kuif M, Oei HL, van der Hoorn JW, Havekes LM, Princen HM, Romijn JA, Smit JW, and Rensen PC. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. Endocrinology 150: 2368-2375, 2009.
8. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, Lafrance JP, Levy A, Garg AX, and Ernst P. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 346: f880, 2013.
9. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37: 1047-1052, 2001.
10. Estelles R, Milian L, Nabah YN, Mateo T, Cerda-Nicolas M, Losada M, Ivorra MD, Issekutz AC, Cortijo J, Morcillo EJ, Blazquez MA, and Sanz MJ. Effect of boldine, secoboldine, and boldine methine on angiotensin II-induced neutrophil recruitment in vivo. J Leukoc Biol 78: 696-704, 2005.
11. Fan LM, Douglas G, Bendall JK, McNeill E, Crabtree MJ, Hale AB, Mai A, Li JM, McAteer MA, Schneider JE, Choudhury RP, and Channon KM. Endothelial cell-specific reactive oxygen species production increases susceptibility to aortic dissection. Circulation 129: 2661-2672, 2014.
12. Farol LT and Hymes KB. Bexarotene: a clinical review. Expert Rev Anticancer Ther 4: 180-188, 2004.
13. Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, and Elisaf MS. Colesevelam plus rosuvastatin 5 mg/day versus rosuvastatin 10 mg/day alone on markers of insulin resistance in patients with hypercholesterolemia and impaired fasting glucose. Metab Syndr Relat Disord 11: 152-156, 2013.
14. Galkina E and Ley K. Immune and inflammatory mechanisms of atherosclerosis (∗). Annu Rev Immunol 27: 165-197, 2009.
15. Golomb BA and Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8: 373-418, 2008.
16. Gonzalez-Navarro H, Abu Nabah YN, Vinue A, Andres-Manzano MJ, Collado M, Serrano M, and Andres V. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J Am Coll Cardiol 55: 2258-2268, 2010.
17. Granger DN and Kubes P. Nitric oxide as antiinflammatory agent. Methods Enzymol 269: 434-442, 1996.
18. Granger DN, Vowinkel T, and Petnehazy T. Modulation of the inflammatory response in cardiovascular disease. Hypertension 43: 924-931, 2004.
19. Greenwood J, Steinman L, and Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6: 358-370, 2006.
20. Guo RW, Yang LX, Li MQ, Liu B, and Wang XM. Angiotensin II induces NF-kappa B activation in HUVEC via the p38MAPK pathway. Peptides 27: 3269-3275, 2006.
21. Hickey MJ and Kubes P. Role of nitric oxide in regulation of leucocyte-endothelial cell interactions. Exp Physiol 82: 339-348, 1997.
22. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, and Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112: 417-428, 2007.
23. Hoffman KB, Kraus C, Dimbil M, and Golomb BA. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class. PLoS One 7: e42866, 2012.
24. Hot A, Lavocat F, Lenief V, and Miossec P. Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Ann Rheum Dis 72: 754-760, 2013.
25. House SD and Lipowsky HH. Leukocyte-endothelium adhesion: microhemodynamics in mesentery of the cat. Microvasc Res 34: 363-379, 1987.
26. Jaffe EA, Nachman RL, Becker CG, and Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756, 1973.
27. Kleemann R, Princen HM, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJ, Kooistra T, and Havekes LM. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE∗3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation 108: 1368-1374, 2003.
28. Landmesser U, Hornig B, and Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 109: II27-II33, 2004.
29. Lassegue B and Griendling KK. NADPH oxidases: functions and pathologies in the vasculature. Arterioscler Thromb Vasc Biol 30: 653-661, 2010.
30. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, and Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation 95: 588-593, 1997.
31. Libby P. Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
32. Loot AE, Schreiber JG, Fisslthaler B, and Fleming I. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med 206: 2889-2896, 2009.
33. Marinissen MJ, Chiariello M, Tanos T, Bernard O, Narumiya S, and Gutkind JS. The small GTP-binding protein RhoA regulates c-jun by a ROCK-JNK signaling axis. Mol Cell 14: 29-41, 2004.
34. Marinou K, Tousoulis D, Antonopoulos AS, Stefanadi E, and Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol 138: 3-8, 2010.
35. Massena S, Christoffersson G, Hjertstrom E, Zcharia E, Vlodavsky I, Ausmees N, Rolny C, Li JP, and Phillipson M. A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116: 1924-1931, 2010.
36. Mateo T, Abu Nabah YN, Abu Taha M, Mata M, Cerda-Nicolas M, Proudfoot AE, Stahl RA, Issekutz AC, Cortijo J, Morcillo EJ, Jose PJ, and Sanz MJ. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 176: 5577-5586, 2006.
37. Mateo T, Naim Abu Nabah Y, Losada M, Estelles R, Company C, Bedrina B, Cerda-Nicolas JM, Poole S, Jose PJ, Cortijo J, Morcillo EJ, and Sanz MJ. A critical role for TNFalpha in the selective attachment of mononuclear leukocytes to angiotensin-II-stimulated arterioles. Blood 110: 1895-1902, 2007.
38. Mira E and Manes S. Immunomodulatory and anti-inflammatory activities of statins. Endocr Metab Immune Disord Drug Targets 9: 237-247, 2009.
39. Montezano AC, Burger D, Paravicini TM, Chignalia AZ, Yusuf H, Almasri M, He Y, Callera GE, He G, Krause KH, Lambeth D, Quinn MT, and Touyz RM. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res 106: 1363-1373, 2010.
40. Moraes LA, Piqueras L, and Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110: 371-385, 2006.
41. Murdoch CE, Chaubey S, Zeng L, Yu B, Ivetic A, Walker SJ, Vanhoutte D, Heymans S, Grieve DJ, Cave AC, Brewer AC, Zhang M, and Shah AM. Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial- mesenchymal transition. J Am Coll Cardiol 63: 2734-2741, 2014.
42. Nabah YN, Mateo T, Estelles R, Mata M, Zagorski J, Sarau H, Cortijo J, Morcillo EJ, Jose PJ, and Sanz MJ. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation 110: 3581-3586, 2004.
43. Nguyen Dinh Cat A, Montezano AC, Burger D, and Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal 19: 1110-1120, 2013.
44. Nickenig G and Murphy TJ. Enhanced angiotensin receptor type 1 mRNA degradation and induction of polyribosomal mRNA binding proteins by angiotensin II in vascular smooth muscle cells. Mol Pharmacol 50: 743-751, 1996.
45. Paintlia AS, Paintlia MK, Singh AK, and Singh I. Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR-alpha-dependent mechanism. Glia 61: 1500-1517, 2013.
46. Pastore L, Tessitore A, Martinotti S, Toniato E, Alesse E, Bravi MC, Ferri C, Desideri G, Gulino A, and Santucci A. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 100: 1646-1652, 1999.
47. Peiro C, Vallejo S, Gembardt F, Palacios E, Novella S, Azcutia V, Rodriguez-Manas L, Hermenegildo C, Sanchez-Ferrer CF, and Walther T. Complete blockade of the vasorelaxant effects of angiotensin-(1-7) and bradykinin in murine microvessels by antagonists of the receptor Mas. J Physiol 591(Pt 9): 2275-2285, 2013.
48. Piqueras L, Sanz MJ, Perretti M, Morcillo E, Norling L, Mitchell JA, Li Y, and Bishop-Bailey D. Activation of PPARbeta/delta inhibits leukocyte recruitment, cell adhesion molecule expression, and chemokine release. J Leukoc Biol 86: 115-122, 2009.
49. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ Res 108: 1002-1016.
50. Ramirez SH, Heilman D, Morsey B, Potula R, Haorah J, and Persidsky Y. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes. J Immunol 180: 1854-1865, 2008.
51. Rashid M, Tawara S, Fukumoto Y, Seto M, Yano K, and Shimokawa H. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J 73: 361-370, 2009.
52. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, and Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359: 2195-2207, 2008.
53. Rius C, Abu-Taha M, Hermenegildo C, Piqueras L, Cerda-Nicolas JM, Issekutz AC, Estan L, Cortijo J, Morcillo EJ, Orallo F, and Sanz MJ. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-kappaB activation and peroxisome proliferator-activated receptor-gamma upregulation. J Immunol 185: 3718-3727, 2010.
54. Rius C, Piqueras L, Gonzalez-Navarro H, Albertos F, Company C, Lopez-Gines C, Ludwig A, Blanes JI, Morcillo EJ, and Sanz MJ. Arterial and venous endothelia display differential functional fractalkine (CX3CL1) expression by angiotensin-II. Arterioscler Thromb Vasc Biol 33: 96-104, 2013.
55. Sanz MJ, Albertos F, Otero E, Juez M, Morcillo EJ, and Piqueras L. Retinoid X receptor agonists impair arterial mononuclear cell recruitment through peroxisome proliferator-activated receptor-gamma activation. J Immunol 189: 411-424, 2012.
56. Scalia R, Gong Y, Berzins B, Freund B, Feather D, Landesberg G, and Mishra G. A novel role for calpain in the endothelial dysfunction induced by activation of angiotensin II type 1 receptor signaling. Circ Res 108: 1102-1111, 2011.
57. Scarisbrick JJ, Morris S, Azurdia R, Illidge T, Parry E, Graham-Brown R, Cowan R, Gallop-Evans E, Wachsmuth R, Eagle M, Wierzbicki AS, Soran H, Whittaker S, and Wain EM. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 168: 192-200, 2013.
58. Shatanawi A, Romero MJ, Iddings JA, Chandra S, Umapathy NS, Verin AD, Caldwell RB, and Caldwell RW. Angiotensin II-induced vascular endothelial dysfunction through RhoA/Rho kinase/p38 mitogen-activated protein kinase/arginase pathway. Am J Physiol Cell Physiol 300: C1181-C1192, 2011.
59. Stalker TJ, Lefer AM, and Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 133: 406-412, 2001.
60. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, and Medford RM. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 100: 1223-1229, 1999.
61. Vakeva L, Ranki A, and Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. Acta Derm Venereol 92: 258-263, 2012.
62. Zhang Y, Naggar JC, Welzig CM, Beasley D, Moulton KS, Park HJ, and Galper JB. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol 29: 1764-1771, 2009.